Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2003

View Archived Issues

SkyePharma updates key product developments

New commercialization and development agreement for Velcade

Lilly Icos submits complete response to FDA for Cialis

Final phase II/III data confirms interim Onco TCS results

Fast track designation awarded to Avastin

FDA delays Estrasorb decision date

Chiesi files IND to advance Formoterol Modulite into clinic

Genmab files CTA to begin phase I/II trial of HuMax-EGFr

Genasense receives fast track designation in CLL

Oxytrex to be studied in phase III pivotal trial

FDA accepts the NDA for trospium

Sustained pain relief found with a new DHE formulation in acute migraine

New cPLA2 inhibitors and their use reported by Wyeth in recent patent

Antimicrobial peptides covered by IPF PharmaCeuticals patent

Toyama claims novel inhibitors of AP-1 transcription factor

Trials confirm the efficacy and safety of bortezomib in multiple myeloma and mantle cell lymphoma

Muscarinic M2/M3 receptor antagonists for urinary incontinence and other uses

The antisense therapeutic EN-101 superior to conventional AChE inhibitors in myasthenia gravis

MS&D designs 5-HT7 antagonists with utility in depression and sleep disorders

Similar pharmacokinetic profiles found for pregabalin in healthy subjects and chronic pain patients

Triazole-based antifungal agent prepared and tested at Meiji Seika

Liarozole granted E.U. orphan drug designation for congenital ichthyosis

Multinational phase III dexanabinol study opens enrollment in U.S.

Antisoma initiates enrollment in phase I study of R-1550 in breast cancer

Endovion shows promising results in preclinical and phase I studies

Phase II trial to evaluate Pentrix in prostate cancer

Benzothiazole-based inhibitor of Lck with good cellular activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...